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Reply from the Authors
We appreciate the comments from Dr. Gai et al con-
cerning the method of detecting proteinuria. A major
finding of our paper was that the degree of proteinuria
shown by dipstick urinalysis was strong as a predictor of
developing end-stage renal disease (ESRD) [1]. We have
recently analyzed the effect of blood pressure on devel-
oping ESRD in the same registry [2]. Comparing the two
papers, we learned that the relative strength of the degree
of dipstick proteinuria (−) to (1+) was similar to that of
different levels of blood pressure. Therefore, slight pro-
teinuria from (±) to 1+ is equally important as that of
mild to moderate hypertension. Although the cumula-
tive incidence of ESRD was low as less than 10 per 1000
screenees in 17 years.
The mass-screening registry, which was done in 1983
used the dipstick urine test (Ames) for detecting protein-
uria. We admit that the sensitivity of dipstick for protein-
uria is lower than that of measuring the protein:creatinine
(P/C) ratio. However, this method was not fully estab-
lished during the early 1980s. In Japan, public support
for the dipstick urine test was started in 1974 for ele-
mentary and junior high school students [3]. There is no
evidence to prove the utility of urine test for preventing
either ESRD or the urinary tract malignancies by mass
screening [4]. According to the 2001 annual report of the
Japanese Society for Dialysis Therapy, the mean age at
start of dialysis was 63.8 years, and the acceptance rate
was more than 250 per million population [5]. Chronic
glomerulonephritis as a primary cause of ESRD has not
increased since 1995. We believe that widespread use of
a screening test from school children to aged popula-
tion may have played a role, at least partly, in this phe-
nomenon. Screenees with dipstick positive proteinuria
(≥2+) are at high risk of developing ESRD [1].
The current cost of dipstick urine test, including both
proteinuria and other tests such as hematuria, ketones,
glucosuria, specific gravity, and pH, is 280 yen ($2.3
United States dollars) in Japan.
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Where have all the lanthanum
salts gone, long time passing?
To the Editor: The D’Haese study [1] should be reas-
suring that one-year treatment of lanthanum carbonate
heals bone diseases in dialysis patients.
However, no comparison is made between plasma lan-
thanum in the two groups of patients (lanthanum- or
calcium-treated), as it is only written that “patients on the
lanthanum group had plasma lanthanum levels slightly in-
creased, with mean levels ranging from 0.51 to 1.08 lg/L,”
and there was no relationship to the “dose administered.”
However, in previous works this “slight increase” was
10 to 25 times higher, from baseline 0.014 to 0.030 lg/L
to 0.346 to 0.776 lg/L, in a dose-dependent fashion
(Table 1), indicating the “existence of some degree of
intestinal absorption.” [2]
Lastly, the sentence “ . . . plasma lanthanum levels
reached a plateau after 12 weeks” is worrying. Where
has lanthanum gone? If biliary excretion is not greatly
increased (to be demonstrated), it accumulates into tis-
sues. The authors wrote that “in light of the past tragic
experience with aluminium . . . information on the effect
of lanthanum carbonate on bone is necessary,” but they
concluded that the five-fold increase in patient bone as
compared with control (after one only year) is not of
Table 1. Blood lanthanum levels increase in a dose-dependent
fashion in the lanthanum group at the end of a 6-week period
treatment in dialysis patientsa
Placebo group (N = 32) Lanthanum group (N = 113)
Lanthanum Blood lanthanum Lanthanum Blood lanthanum
carbonate levels at the carbonate levels at the
dose end of the study dose end of the study
mg/day lg/L mg/day lg/L
0 0.10 ± 0.23 225 0.23 ± 0.23
675 0.80 ± 1.18
1350 0.48 ± 0.43
2250 1.16 ± 1.91
aFrom Joy MS, Hladick G, Finn WF, and the Lanthanum Study Group: Safety
of an investigational phosphate binder lanthanum carbonate in haemodialysis
patients. Poster presented at the American Society Nephrology, Miami, Florida,
November, 1999. J Am Soc Nephrol 10:263A, 1999.
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concern. Astonishingly, they miss the discussion of their
previous results showing lanthanum accumulation and
damage in rat bone [3], the awareness that the effects on
the central nervous system, gut, liver, and other tissues
have never been studied in uremia, and the fact that they
themselves included lanthanum among potential toxic el-
ements in their previous papers [4].
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Reply from the Authors
We thank Dr. Canavese et al [1] for their interest in our
work; however, we disagree that we should neglect the
potential toxicity of lanthanum (La) [2]. During the last
two decades we built up a significant experience on trace
metals and renal osteodystrophy (ROD). The present
clinical trial and experimental studies assessing the pos-
sible effects of La on bone in chronic renal failure (CRF)
were set up upon our advice. Experimental data have
been reported in abstract form at international meet-
ings while manuscripts are submitted for publication. In
these studies, we found that the impaired mineralization
in La-loaded (1000 and 2000 mg/kg/day) CRF rats re-
sulted from the combination of efficient La-phosphate
(P)-binding with reduced vitamin D levels inherent to
CRF. This is corroborated by the findings that: (1) nondi-
etary P repletion restores mineralization; (2) La-loading
to rats with normal renal function does not affect mineral-
ization despite comparable bone La levels; (3) sevelamer
(Renagel, an organic, metal-free P binder) induces a
similar mineralization defect; and (4) La does not affect
osteoblastic activity. Unpublished data further indicate
that the impaired bone mineralization after La loading
improves already after a two-week washout period, while
bone La levels had not changed.
To further examine the potential toxicity of La on bone,
a “bone biopsy–based” study was set up [1]. Here, for
the first time, paired bone biopsies (baseline vs. one-
year follow-up) were taken in dialysis patients to study
the effect of a phosphate binder (i.e., La-carbonate)
on the evolution of ROD and assess its possible accu-
mulation/toxicity in/on bone. We found that, unlike Al
(aluminium), La does not to affect the bone turn-over.
Canavase et al’s concern about the increase in plasma-
La levels in patients receiving La-carbonate is quite right,
although these levels rarely exceed 2 lg/L. In humans,
the gastrointestinal absorption of La has been predicted
to be 0.00003% [3], [i.e., 1300 to 6600 times less than
the values reported for Al (0.04%-0.2%)] [4]. They also
worry about “. . .plasma La-levels reaching a plateau after
12 weeks,” suggesting tissue accumulation in the absence
of an efficient renal function. It should be noted that in
contrast to Al, biliary excretion is the major excretion
route of La. Hence, one may expect that, once equilib-
rium between bone/tissue and plasma-La concentrations
is achieved, the element will be removed from the body
via this pathway, thus minimizing the potential for tissue
accumulation [3]. Preliminary data from ongoing experi-
mental studies showing bone-La levels stabilizing below
5 lg/g after 25 weeks of La loading (2000 mg/kg) support
this statement. The important biliary excretion of La also
implies that, in contrast to various trace metals that are
mainly excreted by the kidney, including Al, CRF patients
are not at an increased risk for accumulation of La.
Finally, we stress that we always did, and still do con-
sider all elements relevant to dialysis as potentially toxic
unless the contrary has been demonstrated. Evidence for
a nontoxic action at the level of bone after one-year treat-
ment with La-carbonate has now been presented in dial-
ysis patients.
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